Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant gelonin (rGel) is a 30 kDa recombinant version of the Type I ribosome-inactivating protein (RIP) originally isolated from the seeds of *Gelonium multiflorum*. As a Type I RIP, it consists of a single polypeptide chain that possesses potent N-glycosidase activity but lacks the cell-binding B-chain found in Type II RIPs like ricin. This structural characteristic renders rGel relatively non-toxic to cells unless it is specifically internalized via a targeting moiety, such as a monoclonal antibody, single-chain Fv fragment, or growth factor. Once inside the cytosol, rGel specifically cleaves a single adenine residue (A4324) from the sarcin/ricin loop of the 28S ribosomal RNA. This action irreversibly inhibits protein synthesis by preventing the binding of elongation factors, ultimately leading to cell death via apoptosis. It is primarily developed as a cytotoxic payload for targeted cancer therapies, including immunotoxins and fusion proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant gelonin.